Almstead Neil Gregory sold $1.9M of PTCT
Almstead Neil Gregory (CHIEF TECHNICAL OPS OFFICER) sold 23,749 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $80.90 ($80.61–$81.21, $1.92M total) across 2 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to change valuation absent additional company news.
Market read
A planned insider sale of ~$1.92M may slightly pressure sentiment, but it is not a fundamental catalyst in the provided text.
What to watch
The filing does not disclose reasons for the sale, whether other insiders are buying, or whether there are concurrent operational updates; without those, price impact is likely limited.
Background
This is an SEC Form 4 insider transaction for PTC Therapeutics, filed on 2026-06-24, covering trades executed on 2026-06-22.
Ticker impact
PTCT insider Almstead Neil Gregory (Chief Technical Ops Officer) sold ~$1.92M of shares via an open-market sale under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless paired with other company-specific news.
Form 4 shows a planned open-market sale with no accompanying operational/financial update in the text, so the information is mostly sentiment/positioning rather than fundamentals.
Market effects
No sector read-through provided; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification/tax planning rather than bearish expectations.
Key entities
- issuerPTC Therapeutics, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderAlmstead Neil Gregory
Chief Technical Ops Officer who sold 23,749 shares under a 10b5-1 plan.
